Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease?

Digestive Diseases and Sciences

Volumn 55, Issue 2, 2010, Pages 226-232

  Feagins, Linda A ^a   Cryer, Byron L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Non steroidal anti inflammatory drugs; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; PLACEBO; ROFECOXIB;

ARTHRITIS; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DIGESTIVE SYSTEM INJURY; DISEASE EXACERBATION; DRUG MECHANISM; DRUG USE; DRUG WITHDRAWAL; ENTERITIS; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; DRUG EFFECT; GASTROINTESTINAL TRACT; RECURRENT DISEASE; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; RECURRENCE; RISK FACTORS;

EID: 76849096442     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1042-7     Document Type: Review

References (38)

1. MP Pusztaszeri RM Genta BL Cryer 2007 Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations Nat Clin Pract Gastroenterol Hepatol 4 442 453 10.1038/ncpgasthep0896 1:CAS:528: DC%2BD2sXosVShu7w%3D 17667993 (Pubitemid 47208894)
2. L Laine K Takeuchi A Tarnawski 2008 Gastric mucosal defense and cytoprotection: bench to bedside Gastroenterology 135 41 60 10.1053/j.gastro. 2008.05.030 1:CAS:528:DC%2BD1cXps1Wltro%3D 18549814 (Pubitemid 351899027)
3. Cryer BL, Spechler SJ. Peptic ulcer disease in Sleisenger & Fordtran's gastrointestinal and liver disease pathophysiology/diagnosis/ management. 8th ed. Philadelphia: Saunders Elsevier; 2006.
4. SD Solomon JJ McMurray MA Pfeffer, et al. 2005 Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 1071 1080 10.1056/NEJMoa050405 1:CAS:528:DC%2BD2MXit1Kqur4%3D 15713944 (Pubitemid 40365348)
5. RS Bresalier RS Sandler H Quan, et al. 2005 Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 1092 1102 10.1056/NEJMoa050493 1:CAS:528:DC%2BD2MXit1Kqu7o%3D 15713943 (Pubitemid 40365350)
6. JL Wallace L Vong 2008 NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs Curr Opin Investig Drugs 9 1151 1156 1:CAS:528:DC%2BD1cXhsVOku7bN 18951293
7. I Tegeder J Pfeilschifter G Geisslinger 2001 Cyclooxygenase-independent actions of cyclooxygenase inhibitors FASEB J 15 2057 2072 10.1096/fj.01-0390rev 1:CAS:528:DC%2BD3MXnsV2msLc%3D 11641233 (Pubitemid 32927924)
8. NM Davies 1999 Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharm Sci 2 5 14 1:CAS:528:DyaK1MXks1Whsr0%3D 10951657
9. PJ Fortun CJ Hawkey 2005 Nonsteroidal antiinflammatory drugs and the small intestine Curr Opin Gastroenterol 21 169 175 10.1097/01.mog.0000153314. 51198.58 1:CAS:528:DC%2BD2MXhtlaitrc%3D 15711208 (Pubitemid 40316198)
10. S Somasundaram G Sigthorsson RJ Simpson, et al. 2000 Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat Aliment Pharmacol Ther 14 639 650 10.1046/j.1365-2036.2000.00723.x 1:CAS:528:DC%2BD3cXjvFSgsLs%3D 10792129 (Pubitemid 30240758)
11. CW Marano LA Garulacan N Ginanni, et al. 2001 Phorbol ester treatment increases paracellular permeability across IEC-18 gastrointestinal epithelium in vitro Dig Dis Sci 46 1490 1499 10.1023/A:1010696005958 1:CAS:528: DC%2BD3MXlvFOhur8%3D 11478501 (Pubitemid 32652618)
12. K-I Tanaka S Suemasu T Ishihara, et al. 2009 Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis Eur J Pharmacol 603 120 132 10.1016/j.ejphar.2008.11.058 1:CAS:528:DC%2BD1MXhtFCjsLg%3D 19101538
13. M Okayama S Hayashi Y Aoi, et al. 2007 Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats Dig Dis Sci 52 2095 2103 10.1007/s10620-006-9597-z 1:CAS:528: DC%2BD2sXoslGisro%3D 17429720 (Pubitemid 47246503)
14. K Takeuchi S Smale P Premchand, et al. 2006 Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease Clin Gastroenterol Hepatol 4 196 202 10.1016/S1542-3565(05)00980-8 1:CAS:528:DC%2BD28Xit1Gqu7c%3D 16469680 (Pubitemid 43199690)
15. CE Eberhart RN Dubois 1995 Eicosanoids and the gastrointestinal tract Gastroenterology 109 285 301 10.1016/0016-5085(95)90296-1 1:CAS:528: DyaK2MXntVant70%3D 7797026
16. TD Wardle L Hall LA Turnberg 1992 Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease Gut 33 1644 1651 10.1136/gut.33.12.1644 1:STN:280:DyaK3s7jvVCmsQ%3D%3D 1487166
17. K Lauritsen LS Laursen K Bukhave, et al. 1988 In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis Gastroenterology 95 11 17 1:STN:280:DyaL1c3isFyqug%3D%3D 2836256
18. CJ Hawkey LM Dube LV Rountree, et al. 1997 A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis Gastroenterology 112 718 724 10.1053/gast.1997.v112.pm9041232 1:CAS:528:DyaK2sXhvFOlsrg%3D 9041232 (Pubitemid 27113796)
19. F D'Acquisto MJ May S Ghosh 2002 Inhibition of nuclear factor kappa B (NF-kB): An emerging theme in anti-inflammatory therapies Mol Interv 2 22 35 10.1124/mi.2.1.22 14993359
20. RJ Xavier DK Podolsky 2007 Unravelling the pathogenesis of inflammatory bowel disease Nature 448 427 434 10.1038/nature06005 1:CAS:528: DC%2BD2sXotFajurs%3D 17653185 (Pubitemid 47123518)
21. ML Cho JW Kang YM Moon, et al. 2006 STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice J Immunol 176 5652 5661 1:CAS:528:DC%2BD28XjsFantLk%3D 16622035
22. P Dharmani V Srivastava V Kissoon-Singh, et al. 2009 Role of intestinal mucins in innate host defense mechanisms against pathogens J Innate Immun 1 123 135 10.1159/000163037 1:CAS:528:DC%2BD1MXhtFOmtLk%3D
23. K Forrest D Symmons P Foster 2004 Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther 20 1035 1043 10.1111/j.1365-2036.2004.02270.x 1:STN:280:DC%2BD2crpsFGitA%3D%3D 15569105 (Pubitemid 39657936)
24. GR Lichtenstein SB Hanauer WJ Sandborn 2009 Management of Crohn's disease in adults: ACG practice guidelines Am J Gastroenterol 104 465 483 10.1038/ajg.2008.168 19174807
25. A Kornbluth DB Sachar 2004 Ulcerative colitis practice guidelines in adults (update): ACG, practice parameters committee Am J Gastroenterol 99 1371 1385 10.1111/j.1572-0241.2004.40036.x 15233681 (Pubitemid 39062279)
26. DS Rampton NI McNeil M Sarner 1983 Analgesic ingestion and other factors preceding relapse in ulcerative colitis Gut 24 187 189 10.1136/gut.24.3.187 1:STN:280:DyaL3s7jtlCiuw%3D%3D 6826100
27. JMM Evans AD McMahon FE Murray, et al. 1997 Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease Gut 40 619 622 1:CAS:528: DyaK2sXksFymtLw%3D 9203940
28. JB Felder BI Korelitz R Rajapakse, et al. 2000 Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study Am J Gastroenterol 95 1949 1954 10.1111/j.1572-0241.2000.02262.x 1:CAS:528: DC%2BD3cXmtl2qtL4%3D 10950041
29. B Shen VW Fazio FH Remzi, et al. 2007 Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders Dig Dis Sci 52 3321 3328 10.1007/s10620-006-9710-3 1:CAS:528:DC%2BD2sXht1Oks7jE 17410449 (Pubitemid 350077174)
30. GF Bonner M Walczak L Kitchen, et al. 2000 Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease Am J Gastroenterol 95 1946 1948 10.1111/j.1572-0241.2000.02263.x 1:CAS:528: DC%2BD3cXmtl2qt7c%3D 10950040
31. GF Bonner A Fakhri SR Vennamaneni 2004 A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease Inflamm Bowel Dis 10 751 757 10.1097/00054725- 200411000-00009 15626893 (Pubitemid 39545220)
32. U Mahadevan EV Jr Loftus WJ Tremaine, et al. 2002 Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease Am J Gastroenterol 97 910 914 10.1111/j.1572-0241.2002.05608.x 1:CAS:528:DC%2BD38XktVKktrk%3D 12008668
33. W Reinisch W Miehsler C Dejaco, et al. 2003 An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia Aliment Pharmacol Ther 17 1371 1380 10.1046/j.1365-2036.2003.01596.x 1:CAS:528:DC%2BD3sXlslCisLc%3D 12786631 (Pubitemid 36774144)
34. L Biancone C Tosti A Geremia, et al. 2004 Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial Aliment Pharmacol Ther 19 755 764 10.1111/j.1365-2036.2004.01907.x 1:CAS:528:DC%2BD2cXktVGnu7c%3D 15043516 (Pubitemid 38496641)
35. WJ Sandborn WF Stenson J Brynskov, et al. 2006 Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study Clin Gastroenterol Hepatol 4 203 211 10.1016/j.cgh.2005.12.002 1:CAS:528:DC%2BD28Xit1Kjsr4%3D 16469681 (Pubitemid 43199691)
36. AM Meyer NN Ramzan RI Heigh, et al. 2006 Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs Dig Dis Sci 51 168 172 10.1007/s10620-006-3103-5 1:CAS:528:DC%2BD28XksVOqtQ%3D%3D 16416231 (Pubitemid 43106356)
37. R Matuk J Crawford MT Abreu, et al. 2004 The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease Inflamm Bowel Dis 10 352 356 10.1097/00054725-200407000-00005 15475742 (Pubitemid 39029177)
38. SA Riley V Mani MJ Goodman, et al. 1990 Why do patients with ulcerative colitis relapse? Gut 31 179 183 10.1136/gut.31.2.179 1:STN:280: DyaK3c7osFeqtA%3D%3D 2311975 (Pubitemid 20092152)